by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
News Bulletin : ADA News Bulletin May 2011
So which patients could you consider referring? If a patient exhibits features of nicotine dependence,15 they could benefit from a referral to their GP. These behaviours include: Smoking soon after waking15 Smoking when ill15 Having difficulty refraining from smoking15 Reporting the first cigarette of the day to be the most difficult to give up15 Smoking more in the morning than the afternoon15 Australians are well aware of the general health risks associated with cigarette smoking, but may not be as aware of the dental impact. Therefore, dentists are in a unique position to counsel their patients on the substantial oral and general health benefits of quitting smoking, as well as referring them on to smoking cessation services.2 With the emerging information on patient acceptance of smoking cessation advice16 and the increasing evidence that tobacco use causes a number of oral health issues,2 dentists have a significant role in supporting patients to quit.2 For more information on CHAMPIX® , please contact Pfizer Medical Information on 1800 675 229. 6 tr eatment at 1mg twice daily. Dos e tapering not required at end of treatment. Patients with sever e r enal impairment: Day 1--3: 0.5mg once daily. Days 4-- end of 12 week treatment: 1mg once daily. Based on TGA approved Product Information dated 15 February 2007 and amended 10 December 2010. PBS DISPENSED PRICE: Initiation pack (53 tablets) $103.76; Maintenance pack (1mg 112 tablets) $231.70; Continuation pack (1mg 56 tablets) $120.42. *Please note changes in Product Information. References: 1. Afifah R, et al. Aust Dent J 2008;53(3):208--16. 2. FDI / WHO (2005) Tobacco or oral health: an advocacy guide for oral health professionals. Edited Beaglehole RH and Benzian HM; FDI World Dental Federation, Ferney Voltaire, France / World Dental Pres s, Lowestoft, UK. 3. CHAMPIX® (varenicline tartrate) Approved Product Infor mation. Pfizer Australia Pty Ltd. 4. Jorenby DE, et al. JAMA 2006;296:56--63. 5. Coe JW, et al. J Med Chem 2005;48:3474--7. 6. European Public Assessment Report (EPAR). CHAMPIX: Scientific discussion 2009. (Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _Product_Information/human/000699/WC500025251.pdf. 7. Nides M, et al. Am J Health Behav 2008;32(6):664--75. 8. Nides M, et al. Arch Intern Med 2006;166:1561--8. 9. West R. Psychopharmacology 2008;197:371--7. 10. Keating GM, et al. CNS Drugs 2006;20(11):945--60. 11. Gonzales DH et al. JAMA 2006;296:47--55. 12. Aubin HJ, et al. Thorax 2 0 0 8 ; 6 3 : 717--24. 13. Pharmaceutical Benefits Schedule, November 2010. 14. To n s t ad S, et al. JAMA 2006;296:64--71. 15. Smoking Cessation Guidelines for Australian General Practice. Practice Handbook, 2004. 16. Coleman T, et al. Br J Gen Pract 1999;49:557--8. Pfizer Australia Pty Limited ABN 50 008 422 348 w ww.pfizer.com.au Pfizer Medical Information: 1800 675 229. P3595 03/11 PPU1048/ADA. Pfizer Australia Pty Limited 38--42 Wharf Road, West Ryde NSW 2114
ADA News Bulletin April 2011
ADA News Bulletin June 2011